Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lisdexamfetamine + mixed amphetamine salts immediate release
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This entry refers to the comparative evaluation of two central nervous system stimulant medications, lisdexamfetamine dimesylate (LDX) and mixed amphetamine salts immediate release (MAS-IR), developed by Shire (now part of Takeda) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). LDX is a long-acting prodrug that is enzymatically converted in the blood to the active stimulant d-amphetamine, providing a gradual and sustained therapeutic effect. MAS-IR is an immediate-release formulation containing a mixture of four amphetamine salts (d-amphetamine saccharate, d-amphetamine sulfate, l-amphetamine aspartate, and l-amphetamine sulfate). Both medications function by increasing the synaptic concentrations of the catecholamine neurotransmitters dopamine and norepinephrine through the inhibition of their reuptake and the promotion of their release from presynaptic neurons. The specific context provided describes a Phase I crossover study (NCT00544115) designed to evaluate the sensitivity of a computerized cognitive test battery in adults with ADHD treated with these agents.
- Brand names
- VyvanseAdderall
- Other names
- Lisdexamfetamine DimesylateMixed Amphetamine SaltsMixed Amphetamine Salts Immediate Release
02
Targets
TAAR1 (Trace amine-associated receptor 1)NET (Norepinephrine Transporter)VMAT2 (Vesicular monoamine transporter 2)MAOB (Monoamine oxidase B)SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)MAOA (Monoamine oxidase A)
Beyond the preview
Go deeper on lisdexamfetamine + mixed amphetamine salts immediate release.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lisdexamfetamine + mixed amphetamine salts immediate release.